Background {#Sec1}
==========

Myopia is a common visual disorder with increasing prevalence among developed countries of the world. Current evidence suggests that myopia affects a large portion of the world population, reaching over 90% in Asian countries, and typically develops in children of 6 to 8 years of age. Over the past half-century, rapid progress of myopia has been reported. Treatment of myopia at an early stage is of paramount importance, as shortsightedness poses a significant risk for several ocular disorders which could result in blindness. These conditions include retinal detachment, glaucoma, cataract, and macular degeneration \[[@CR1]\].

A number of optical and pharmacological modalities have been widely investigated for restriction of myopia progression \[[@CR2], [@CR3]\]. Clinical trials on spectacles, rigid gas permeable contact lenses, progressive addition lenses, and soft contact lenses have revealed little or no long-term efficacy of these interventions in myopia control \[[@CR4], [@CR5]\]. Both tropicamide combined with bifocals and timolol have also failed to show a significant effect on slowing myopia progression \[[@CR6], [@CR7]\]. Two randomized controlled trials on pirenzepine revealed encouraging findings; however, research has not been continued for this agent \[[@CR8]--[@CR10]\]. Contradictory evidence exists regarding the effect of undercorrection on myopia progression. Two randomized controlled trials reported that undercorrection enhances myopia development \[[@CR11], [@CR12]\]. Recent evidence shows that undercorrection restricts myopia progression compared to full correction in already myopic children, which is in line with former findings from animal studies \[[@CR13]\]. Acupuncture has also been investigated for myopia control, but insufficient evidence exists regarding its appropriateness for clinical use \[[@CR14]\].

Recent studies have reported positive findings for atropine eye drops and orthokeratology in the management of juvenile myopia \[[@CR15]--[@CR18]\]. In addition, bifocal and multifocal soft contact lenses designed with new technology constitute an emerging treatment with promising results \[[@CR19]\]. Increased outdoor exposure has also been described to have a protective effect on myopia development \[[@CR20]\].

Currently, there are no generally accepted guidelines on the treatment of myopic progression. Various refractive and pharmaceutical interventions have been investigated, but atropine which appears the most beneficial agent has not been approved by the Food and Drug Administration (FDA). Associated adverse events have prevented efficient interventions from becoming widely adopted for myopia treatment \[[@CR21], [@CR22]\]. Myopia causes considerable medical and economic impact on society. The cost of treatment is significant to both individuals and society. Annual expenses for myopia treatment are estimated to be greater than for other ocular pathologies, as well as for non-ocular chronic conditions. The quality of life of individuals is also affected due to functional, cosmetic, and psychological implications \[[@CR23]--[@CR25]\].

Further investigation is warranted, due to the existing increasing prevalence of myopia in the worldwide population \[[@CR26]\]. Existing evidence, although at a high level, has failed to convince ophthalmologists to uniformly embrace treatments for myopia progression control. A study design that has recently gained interest is the overview of systematic reviews or umbrella review that attempts to bring together and treat synthetically the evidence from systematic reviews with or without meta-analyses in a given domain \[[@CR27]--[@CR29]\]. Thus, there is no overview in existing literature synthesizing the information provided by systematic reviews and meta-analyses on slowing myopia progression in children, and this is the aim of the present study.

Methods {#Sec2}
=======

Protocol and registration {#Sec3}
-------------------------

This overview has been registered in the PROSPERO database (CRD42017068204) and has been prepared in consultation with the PRISMA-P statement \[[@CR30], [@CR31]\]. PRISMA-P checklist is provided as Additional file [1](#MOESM1){ref-type="media"}. Any amendments to the protocol until completion of the overview shall be provided with reasons and shall be available to public view.

Information sources and search strategy {#Sec4}
---------------------------------------

A purposive literature search will be conducted in the Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), and Health Technology Assessment (HTA) Database via Centre for Reviews and Dissemination (CRD) using the keyword "myopia." A more comprehensive search strategy will be applied in MEDLINE and EMBASE, using medical subject headings (MeSH) and text words related to spectacles, contact lenses, anti-muscarinic agents, myopia, and children \[[@CR4], [@CR32]\]. Database search date is 15 January 2017. For all included studies, reference lists will be also searched. MEDLINE search strategy and keywords are provided in Additional file [2](#MOESM2){ref-type="media"}. No language, study type, or date restrictions will be used.

Research question {#Sec5}
-----------------

What is the efficacy and safety of optical and pharmacological interventions used to control myopia progression in children and adolescents?

Eligibility criteria {#Sec6}
--------------------

The overview question being addressed is best described by the following PICOS (participants, intervention, comparator, outcomes, study design) format.

### Participants {#Sec7}

Our overview targets are children and adolescents, equal to or less than 18 years of age (at baseline), diagnosed with myopia defined as spherical equivalent refraction ≤ − 0.25 diopters, with or without astigmatism, and without any ocular comorbidities including strabismus and amblyopia. Animals, adult population, patients not suffering from myopia, or patients with myopia and strabismus/amblyopia will be excluded. Studies related to surgical interventions for myopia correction, e.g., refractive surgery will not be considered.

### Interventions {#Sec8}

Any optical or pharmacological intervention for controlling myopia progression will be identified. No restriction on duration and dose (if applicable) of treatment will be imposed.

### Comparators {#Sec9}

Comparators will be the use of single-vision spectacles, contact lenses, (sham) acupuncture, or placebo for controlling myopia progression. No restriction on duration of treatment will be imposed.

### Outcomes {#Sec10}

Our primary outcomes will regard myopia progression and axial elongation as efficacy criteria. Myopia progression will be assessed as mean change in refractive error, measured in diopters, per year. Mean change in axial length, measured in millimeters, per year, will also be evaluated. Outcomes reporting a change in other than a 12-month period will also be accepted and described. Reported adverse events will be regarded as safety criteria. A descriptive approach of side effects will be performed, and odd ratios will be presented, if provided by the authors.

### Study design {#Sec11}

We will consider systematic reviews or meta-analyses of randomized controlled trials (RCTs), pseudo-RCTs, and cohort and case-control studies. Network meta-analyses, if available, will also be reviewed. In order to ensure literature saturation, we aim to consider any recently published RCTs found to not have been included in the meta-analyses. Should recent RCTs be identified, these will also be appraised and their findings will be presented and discussed. No language limitation will be imposed. Only human studies with full text available will be analyzed.

Systematic reviews or meta-analyses of poor quality cohort studies, case series, case reports, or expert opinions will not be considered. Narrative reviews that do not systematically search the literature and do not critically appraise the quality of included studies will be excluded.

Data management and extraction {#Sec12}
------------------------------

Two independent authors will perform all screening steps. Title and abstract screening will be conducted with the Mendeley citation management software. The overview authors will screen the titles and abstracts against the eligibility criteria and obtain full reports for all titles that appear to meet the inclusion criteria, or where there is uncertainty. One team of two independent overview authors will manage data in duplicate from each eligible study, using a data collection form in Microsoft Excel, designed specifically to include all the data required. We will only extract data of the included systematic reviews or meta-analyses and not directly from the primary studies, as this process would be beyond the scope of our overview. In cases of disagreement, consensus will be reached with the help of a third author.

For each included study, information will be extracted on the type of included study (systematic review, systematic review and meta-analysis, meta-analysis, or network meta-analysis); publication date; number of databases sourced and searched; last literature search; type of included primary studies (randomized controlled trials, observational studies, or both); country/countries of origin of studies included in each review; number of primary studies in each review; source of financial support (if any); participants' characteristics (age range); total sample size (or range of sizes of primary studies); type of treatment (optical or pharmaceutical) and dose when applicable; type of control (optical, pharmaceutical, or placebo) and dose when applicable; follow-up period; outcomes that are relevant to our overview question; results; major conclusions; instrument used to appraise the primary studies and the rating of their quality; metric used and effect size (for meta-analyses); *p*-value (for meta-analyses); confidence intervals (for meta-analyses); additional analyses (e.g. subgroup analysis, meta-regression, sensitivity analysis, for meta-analyses); and handling of heterogeneity (fixed/random effects model, funnel plot, for meta-analyses).

Risk-of-bias assessment {#Sec13}
-----------------------

Two overview authors will independently assess the methodological quality of the included systematic reviews and meta-analyses using the ROBIS tool. A qualitative, domain-based assessment will be performed with ROBIS, evaluating eligibility criteria, identification and selection of primary studies, data collection and study appraisal, and synthesis and findings. A tabular presentation of ROBIS assessment for each included review will be provided and will enable comparisons between studies and detection of the possible presence of bias \[[@CR33]\]. We will also provide a table presenting a risk-of-bias assessment of primary studies and relevant tool utilized by each eligible review. If the risk of bias of primary studies has not been evaluated by one or more reviews, we will appraise these studies and present our assessment in a relevant table. The strength of evidence for each outcome of interest across the eligible systematic reviews will be evaluated by two independent authors using the GRADE rating \[[@CR34]--[@CR36]\]. In order to minimize the subjectivity of quality assessment process, a third reviewer will be involved to resolve any discrepancies.

The list of included primary studies will be reviewed in order to identify overlapping studies considered in two or more eligible reviews. We will generate a citation matrix presenting all the included reviews and primary publications. We will estimate the overlap by calculating the corrected covered area (CCA), to assess if specific primary studies are overrepresented. CCA will reflect the degree of actual overlap, as it is not influenced by large reviews. Should high or very high overlap be detected, we will retain the review which will be (1) the most recent, (2) containing a higher amount of information, and (3) the most rigorous in terms of methodology, as assessed by ROBIS tool and GRADE scale. We will examine and record whether the results of overlapping studies are concordant, and if many relevant primary studies would be excluded as a result of the above approach \[[@CR37]\].

Two independent overview authors will also examine possible presence of meta-biases, including publication bias, selective outcome reporting, and dual co-authorship. Handling of heterogeneity for meta-analyses and other potential sources of bias will be described \[[@CR38]--[@CR41]\].

Data synthesis {#Sec14}
--------------

To summarize findings, a descriptive synthesis will be performed. Specifically, we will provide tables that include summaries of study characteristics, quality assessment, and major conclusions. Methodological rigor and quality of evidence of the included studies will be reflected by ROBIS and GRADE assessments. The extent of overlapping primary studies will be displayed in our citation matrix, and the corrected covered area (CCA) will provide an estimate of the actual overlap. Our overview outcomes regarding the efficacy and safety of myopia treatments will be stratified and presented according to the type of intervention. For studies examining the same interventions, we will state whether the reported conclusions are concordant. Should any recent randomized controlled trials be found to not have been included in the meta-analyses, these will also be appraised and their findings will be presented and discussed.

Discussion {#Sec15}
==========

Currently, no consensus has been reached regarding the management of myopic progression and no universal guidelines have been established. This study aims to qualitatively synthesize systematic reviews and meta-analyses in order to identify and appraise high-level research evidence regarding myopia control in children and adolescents. Efficient interventions will be identified and side effects will be reported. Recently published randomized controlled trials will also be presented to provide an insight into the most recent available evidence for retarding myopia progression. The results may guide future research in this area and contribute to guideline development.

Additional files
================

 {#Sec16}

Additional file 1:PRISMA-P checklist. (DOCX 36 kb) Additional file 2:MEDLINE search strategy. (DOCX 16 kb)
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